Raymond James analyst Steven Seedhouse lowered the firm’s price target on Mirum Pharmaceuticals to $84 from $88 and keeps a Strong Buy rating on the shares. Mirum pre-announced FY22 Livmarli sales that were above consensus and announced CFO Ian Clements will be departing the company, which "seems in large part a personal decision and is amicable," Seedhouse tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MIRM:
- Albireo acquisition ‘good news’ for Mirum Pharmaceuticals, says Piper Sandler
- Mirum Pharmaceuticals sees FY22 Livmarli net product sales $74M
- Mirum Pharmaceuticals sees FY22 revenue $74M, consensus $72.85M
- Mirum Pharmaceuticals announces EC marketing authorization for Livmarli
- Mirum Pharmaceuticals to discontinue OHANA study of volixibat in ICP
